Skip to main content
Fig. 3 | BMC Medical Genomics

Fig. 3

From: Comprehensive analysis of BTNL9 as a prognostic biomarker correlated with immune infiltrations in thyroid cancer

Fig. 3

Kaplan-Meier survival curves for patients with THCA from KM plotter web-based tool. (A) Higher expression of BTNL9 was associated with better RFS in patients with THCA. (B) Subgroup analysis indicated that BTNL9 expression was associated with more favorable RFS in female THCA patients. (C)BTNL9 expression was associated with more favorable RFS in THCA patients with low neoantigen load. (D) Higher expression of BTNL9 was associated with better RFS in patients with Stage 1 THCA. (E) Higher expression of BTNL9 was associated with better OS in patients with Stage 4 THCA.

RFS, relapse free survival; OS, overall survival; THCA, thyroid carcinoma

Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us